Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-HT6 receptor

US8293913B2 · kind B2 · utility

Assignee

• Abbott GmbH & Co. KG · DE

Inventors

• Sean Colm Turner · Ludwigshafen, DE
• Wilfried Braje · Ludwigshafen, DE
• Andreas Haupt · Ludwigshafen, DE
• Udo Lange · Ludwigshafen, DE
• Karla Drescher · Ludwigshafen, DE
• Karsten Wicke · Ludwigshafen, DE
• Liliane Unger · Ludwigshafen, DE
• Mario Mezler · Ludwigshafen, DE
• Wolfgang Wernet · Ludwigshafen, DE
• Matthias Mayrer · Biblis, DE

Key dates

• Filing date: Aug 6, 2008
• Grant date: Oct 23, 2012
• Expiry date: Aug 6, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to novel quinoline compounds of the formula (I) and to the salts thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor. In formula (I) R is a moiety of the formula (R) wherein * indicates the binding site to the quinolinyl radical and wherein A, B, X′, Y, Q, R1, R2, R3, R4, R5, m, n, p, q, Ra, Rb, X and Ar are as defined in claim 1.